Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.
about
Antithrombin III for critically ill patientsRenal replacement therapy in acute kidney injury: controversy and consensusClinical review: Patency of the circuit in continuous renal replacement therapyHemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgeryThe effects of continuous venovenous hemofiltration on coagulation activation.Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis.Vascular access sites for acute renal replacement in intensive care units.Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysisHow to deal with dialysis catheters in the ICU setting.Antithrombin III Doses Rounded to Available Vial Sizes in Critically Ill Pediatric Patients.Outcomes of non-tunneled non-cuffed hemodialysis catheters in patients on chronic hemodialysis in a resource limited sub-Saharan Africa setting.Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption.Antithrombin III Utilization in a Large Teaching Hospital.Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group "Renal Replacement Therapies in Critically Ill Patients" of the Italian Society of Nephrology.
P2860
Q24242053-F3F81D18-81DE-4F5B-835C-B643D3BEB7DAQ26998864-D6CDA248-00F3-495C-9B57-E4A240C9E801Q33375906-7F503EC1-F2EA-4678-8F19-6D07664CFEADQ33612746-AE19B487-A5F8-4D41-A55A-AA1E45740BB9Q34441153-DD7777B1-C55E-405F-8C95-B724234D3228Q35544719-08668EF9-F070-41E1-88B5-3CC65FE13E01Q35629861-17AD8ABA-018C-4438-97BE-41534870A99BQ35692489-3F47B09B-5F64-4433-A680-139279D5C089Q36285489-2CDA5285-54B1-4175-B5A8-7CCA049B5002Q36478648-9D4DC5FF-1160-4F44-8F51-67FAB44B119FQ39197597-1AC81438-B1DC-49B5-9C5C-3FB74FFE422EQ40192509-98651DF9-9D01-4BE1-9E57-AE7B683FB050Q40603847-DC00150D-50F8-4F8C-88DC-E1952D17EF9CQ42771225-7F5CF4AA-D7D3-4C2D-BBFB-BF2C40F73B30Q42848627-CCE387A0-4A7A-49D4-8310-B5D6E030CD4DQ51018006-D55E5DC6-4200-4615-9C3D-9A82A204279B
P2860
Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antithrombin supplementation f ...... c shock: a case-control study.
@ast
Antithrombin supplementation f ...... c shock: a case-control study.
@en
Antithrombin supplementation f ...... c shock: a case-control study.
@nl
type
label
Antithrombin supplementation f ...... c shock: a case-control study.
@ast
Antithrombin supplementation f ...... c shock: a case-control study.
@en
Antithrombin supplementation f ...... c shock: a case-control study.
@nl
prefLabel
Antithrombin supplementation f ...... c shock: a case-control study.
@ast
Antithrombin supplementation f ...... c shock: a case-control study.
@en
Antithrombin supplementation f ...... c shock: a case-control study.
@nl
P2093
P2860
P356
P1433
P1476
Antithrombin supplementation f ...... c shock: a case-control study.
@en
P2093
Bruno Bouchet
Cédric Bruel
Cédric Daubin
Damien du Cheyron
Michel Ramakers
Pierre Charbonneau
P2860
P356
10.1186/CC4853
P577
2006-01-01T00:00:00Z
P5875
P6179
1001325142
1018186726